Jeffrey W. Albers Sells 11,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 11,033 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total value of $1,000,582.77. Following the transaction, the director now directly owns 165,017 shares in the company, valued at approximately $14,965,391.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Blueprint Medicines Trading Up 0.1 %

Shares of NASDAQ BPMC opened at $94.86 on Friday. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60. The company has a market cap of $5.81 billion, a price-to-earnings ratio of -11.35 and a beta of 0.63. Blueprint Medicines Co. has a 12-month low of $41.54 and a 12-month high of $101.00. The stock’s 50 day simple moving average is $86.36 and its 200 day simple moving average is $72.91.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The business’s revenue for the quarter was up 85.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.65) EPS. Equities research analysts expect that Blueprint Medicines Co. will post -5.42 EPS for the current year.

Analyst Ratings Changes

BPMC has been the subject of several analyst reports. Barclays raised their price target on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 13th. Wedbush restated an “outperform” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 5th. Wells Fargo & Company lifted their target price on shares of Blueprint Medicines from $86.00 to $115.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Raymond James boosted their target price on shares of Blueprint Medicines from $85.00 to $100.00 and gave the company a “strong-buy” rating in a report on Friday, December 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Blueprint Medicines from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Four analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of “Hold” and an average target price of $85.43.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Blueprint Medicines during the 4th quarter valued at about $9,768,000. Vanguard Group Inc. grew its holdings in shares of Blueprint Medicines by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after acquiring an additional 147,827 shares in the last quarter. Readystate Asset Management LP acquired a new stake in Blueprint Medicines in the fourth quarter valued at $3,692,000. Blue Owl Capital Holdings LP acquired a new position in shares of Blueprint Medicines during the 4th quarter worth approximately $6,631,000. Finally, Legal & General Group Plc boosted its holdings in shares of Blueprint Medicines by 0.9% during the 4th quarter. Legal & General Group Plc now owns 58,964 shares of the biotechnology company’s stock worth $5,439,000 after buying an additional 508 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.